Immune checkpoints as therapeutic targets in autoimmunity
Antibodies that block the immune checkpoint receptors PD1 and CTLA4 have revolutionized the treatment of melanoma and several other cancers, but in the process, a new class of drug side effect has emerged-immune related adverse events. The observation that therapeutic blockade of these inhibitory re...
Váldodahkkit: | Paluch, C, Santos, A, Anzilotti, C, Cornall, R, Davis, S |
---|---|
Materiálatiipa: | Journal article |
Giella: | English |
Almmustuhtton: |
Frontiers Media
2018
|
Geahča maid
-
Immune Checkpoints as Therapeutic Targets in Autoimmunity
Dahkki: Christopher Paluch, et al.
Almmustuhtton: (2018-10-01) -
Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
Dahkki: Yujia Zhai, et al.
Almmustuhtton: (2021-04-01) -
Combination CD200R/PD-1 blockade in a humanised mouse model
Dahkki: Fellermeyer, M, et al.
Almmustuhtton: (2023) -
Manipulating immune checkpoint signalling pathways with antibodies
Dahkki: Paluch, C
Almmustuhtton: (2019) -
Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
Dahkki: Lauren S. Fane, et al.
Almmustuhtton: (2022-09-01)